- Home
- NVCR vs DFIN Comparison
NVCR vs DFIN Comparison
Compare NVCR & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- DFIN
- Stock Information
- Founded
- NVCR 2000
- DFIN 1983
- Country
- NVCR Switzerland
- DFIN United States
- Employees
- NVCR N/A
- DFIN N/A
- Industry
- NVCR Medical/Dental Instruments
- DFIN Other Consumer Services
- Sector
- NVCR Health Care
- DFIN Consumer Discretionary
- Exchange
- NVCR Nasdaq
- DFIN Nasdaq
- Market Cap
- NVCR 1.3B
- DFIN 1.4B
- IPO Year
- NVCR 2015
- DFIN N/A
- Fundamental
- Price
- NVCR $11.25
- DFIN $44.69
- Analyst Decision
- NVCR Buy
- DFIN Strong Buy
- Analyst Count
- NVCR 7
- DFIN 2
- Target Price
- NVCR $28.64
- DFIN $63.50
- AVG Volume (30 Days)
- NVCR 1.5M
- DFIN 351.8K
- Earning Date
- NVCR 10-30-2025
- DFIN 10-29-2025
- Dividend Yield
- NVCR N/A
- DFIN N/A
- EPS Growth
- NVCR N/A
- DFIN N/A
- EPS
- NVCR N/A
- DFIN 1.12
- Revenue
- NVCR $642,269,000.00
- DFIN $750,800,000.00
- Revenue This Year
- NVCR $9.54
- DFIN N/A
- Revenue Next Year
- NVCR $5.70
- DFIN $4.20
- P/E Ratio
- NVCR N/A
- DFIN $40.24
- Revenue Growth
- NVCR 11.17
- DFIN N/A
- 52 Week Low
- NVCR $10.70
- DFIN $37.80
- 52 Week High
- NVCR $34.13
- DFIN $69.93
- Technical
- Relative Strength Index (RSI)
- NVCR 35.05
- DFIN 35.74
- Support Level
- NVCR $10.70
- DFIN $44.78
- Resistance Level
- NVCR $12.01
- DFIN $47.75
- Average True Range (ATR)
- NVCR 0.57
- DFIN 1.88
- MACD
- NVCR -0.11
- DFIN 0.00
- Stochastic Oscillator
- NVCR 15.48
- DFIN 8.03
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.